[go: up one dir, main page]

MXPA02012068A - Formulaciones liposomales inhibidoras de la timidilato de benzoqunazolina sintasa. - Google Patents

Formulaciones liposomales inhibidoras de la timidilato de benzoqunazolina sintasa.

Info

Publication number
MXPA02012068A
MXPA02012068A MXPA02012068A MXPA02012068A MXPA02012068A MX PA02012068 A MXPA02012068 A MX PA02012068A MX PA02012068 A MXPA02012068 A MX PA02012068A MX PA02012068 A MXPA02012068 A MX PA02012068A MX PA02012068 A MXPA02012068 A MX PA02012068A
Authority
MX
Mexico
Prior art keywords
synthase inhibitor
thymidylate synthase
liposomal
inhibitor formulations
benzoquinazoline thymidylate
Prior art date
Application number
MXPA02012068A
Other languages
English (en)
Inventor
Gerard M Jensen
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of MXPA02012068A publication Critical patent/MXPA02012068A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan formulaciones de inhibidor de la timidilato de benzoquinazolina sintasa encapsuladas, liposomales. Los liposomas tienen farmacocinetica mejorada y mejor eficacia como agentes antitumor en comparacion con el farmaco libre. Las formulaciones incluyen liposomas que comprenden al menos una fosfatidilcolina, un colesterol y un inhibidor de la timidilato de benzoquinazolina sintasa.
MXPA02012068A 2000-06-09 2001-06-06 Formulaciones liposomales inhibidoras de la timidilato de benzoqunazolina sintasa. MXPA02012068A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21059200P 2000-06-09 2000-06-09
PCT/US2001/018224 WO2001095884A2 (en) 2000-06-09 2001-06-06 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations

Publications (1)

Publication Number Publication Date
MXPA02012068A true MXPA02012068A (es) 2004-08-19

Family

ID=22783495

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012068A MXPA02012068A (es) 2000-06-09 2001-06-06 Formulaciones liposomales inhibidoras de la timidilato de benzoqunazolina sintasa.

Country Status (15)

Country Link
US (2) US6689381B2 (es)
EP (1) EP1286661A2 (es)
JP (1) JP2004503491A (es)
KR (1) KR100851957B1 (es)
CN (1) CN1446080A (es)
AU (2) AU7526901A (es)
BR (1) BR0111541A (es)
CA (1) CA2412165A1 (es)
IL (2) IL153230A0 (es)
MX (1) MXPA02012068A (es)
NZ (1) NZ522842A (es)
PL (1) PL360470A1 (es)
TW (1) TWI282741B (es)
WO (1) WO2001095884A2 (es)
ZA (1) ZA200209524B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
JP2005529076A (ja) 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
US7166595B2 (en) 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
US7038048B2 (en) 2002-05-23 2006-05-02 Cytokinetics, Inc. 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
CA2489367A1 (en) 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004009036A2 (en) 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
JP2006501306A (ja) 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
CA2506749A1 (en) * 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
JP5032849B2 (ja) * 2004-01-14 2012-09-26 ギリアード サイエンシーズ， インコーポレイテッド 薬物送達に有用な脂質ベースの分散物
WO2006012502A2 (en) * 2004-07-23 2006-02-02 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
EP1773298A1 (en) * 2004-08-06 2007-04-18 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
JP4950890B2 (ja) * 2004-09-13 2012-06-13 ギリアード サイエンシーズ， インコーポレイテッド 動物に対する鉄の送達
US20060159735A1 (en) * 2005-01-20 2006-07-20 Nicholas Bonham Method of reclaiming drug compound from liposomal drug manufacturing stream
WO2006078253A1 (en) * 2005-01-20 2006-07-27 Osi Pharmaceuticals, Inc. Method of reclaiming drug compound osi-7904 from liposomal drug manufacturing stream
EP1745788A1 (de) * 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie
CN100348194C (zh) * 2005-07-26 2007-11-14 康辰医药发展有限公司 盐酸洛拉曲克的脂质体制剂及其制备方法
CA2631875A1 (en) * 2005-12-06 2007-10-04 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
US9493810B2 (en) * 2012-06-07 2016-11-15 Pioma, Inc. 5-ALA for detection of brain tumors
MX363455B (es) * 2012-07-18 2019-03-25 Onyx Therapeutics Inc Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
WO2018031967A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
CA3033077C (en) 2016-08-12 2024-06-18 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
CN111954529A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化氨甲蝶呤及其用途
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
WO2019157121A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
WO2019157120A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
JP7491572B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
US12246015B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
JP7490239B2 (ja) 2018-02-07 2024-05-27 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化ペメトレキセドおよびその使用
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
CA3090391A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
WO2019157123A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
WO2019157146A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
WO2019160736A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
CA3090992A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
EP3752158A4 (en) 2018-02-14 2022-03-09 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF
EP3752157A4 (en) 2018-02-14 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
EP3752155A4 (en) 2018-02-14 2022-03-16 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMATE METHOTREXATE AND USES THEREOF
WO2025095862A1 (en) * 2023-10-30 2025-05-08 National University Of Singapore A composition, a method of making the composition and its uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460577A (en) * 1977-09-30 1984-07-17 Farmitalia Carlo Erba S.P.A. Pharmaceutical compositions consisting or consisting essentially of liposomes, and processes for making same
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4755388A (en) * 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
US4753788A (en) 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
GB9013615D0 (en) 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
WO1994011030A1 (en) 1992-11-13 1994-05-26 The Ohio State University Research Foundation C-glycoside analogues of n-(4-hydroxyphenyl)retinamide-o-glucuronide
JPH11199488A (ja) * 1998-01-09 1999-07-27 Sankyo Co Ltd 抗腫瘍薬のリポソーム化製剤

Also Published As

Publication number Publication date
CN1446080A (zh) 2003-10-01
AU7526901A (en) 2001-12-24
IL153230A (en) 2009-02-11
US20040057990A1 (en) 2004-03-25
KR100851957B1 (ko) 2008-08-12
WO2001095884A3 (en) 2002-06-13
PL360470A1 (en) 2004-09-06
TWI282741B (en) 2007-06-21
AU2001275269B2 (en) 2006-07-13
BR0111541A (pt) 2003-07-01
JP2004503491A (ja) 2004-02-05
EP1286661A2 (en) 2003-03-05
CA2412165A1 (en) 2001-12-20
ZA200209524B (en) 2003-11-22
KR20030038552A (ko) 2003-05-16
IL153230A0 (en) 2003-07-06
US6689381B2 (en) 2004-02-10
US20020034538A1 (en) 2002-03-21
WO2001095884A2 (en) 2001-12-20
NZ522842A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
MXPA02012068A (es) Formulaciones liposomales inhibidoras de la timidilato de benzoqunazolina sintasa.
PL351487A1 (en) Encapsulation of bioactive complexes in liposomes
WO2004047802A3 (en) Liposomal formulations
DE60138566D1 (en) Selbstformende thermodynamisch stabile liposome
WO2002000194A3 (en) Polymeric micelle compositions
AU4357800A (en) Intracellular pharmaceutical targeting
AU2001270300A1 (en) Drug delivery formulations and targeting
AU7306201A (en) Substituted-triazolopyrimidines as anticancer agents
MXPA03001890A (es) Poliarilcarboxamidas utiles como agentes reductores de lipidos.
EP1198256A4 (en) PEPTIDES-LIPIDS CONJUGATES, LIPOSOMES AND SUPPORT OF LIPOSOMIC DRUGS
WO1999013816A3 (en) Liposomal camptothecin formulations
ZA200200743B (en) Preserved pharmaceutical formulations.
WO2002072011A3 (en) Stabilized therapeutic and imaging agents
AU5983900A (en) Combined preparations comprising antitumor agents
IL152593A0 (en) Liposome drug delivery
AU2001234114A1 (en) Drugs containing combined active ingredients
MXPA03004465A (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos.
WO2002015959A3 (en) Compounds and compositions for delivering active agents
AU2001234089A1 (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
AU3408901A (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
AUPQ761100A0 (en) Lipophilic medicament
DE50208813D1 (en) (ester)-lysolecithine in liposomen
EP1308156A4 (en) AGGREGATE SOLID DISPERSION WITH IMPROVED SOLUBILITY
AU2001268653A1 (en) Combination hiv therapy including camptothecin
WO2002048380A3 (en) Glycosilated cationic lipids for liposomes used in drug delivery